GlassScriptPhysician profile
Javier Chinen
NPI 1013026699
$2,303.21
in general payments reported to CMS, 2019-2025
18 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $116 · 2021: $282 · 2022: $977 · 2023: $213 · 2024: $150 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $420.90 | 2020-2024 | Fasenra |
| Glaxosmithkline, LLC. | $393.09 | 2019-2025 | Nucala |
| Grifols USA, LLC | $290.76 | 2021-2023 | Xembify |
| Pharming Healthcare, INC. | $179.32 | 2019-2025 | Ruconest |
| Adma Biomanufacturing LLC | $170.83 | 2022 | |
| Genzyme Corporation | $135.74 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $127.19 | 2019-2022 | |
| Incyte Corporation | $125.99 | 2022 | |
| Optinose US, INC. | $118.42 | 2019 | |
| Kaleo, INC. | $94.02 | 2022-2024 | Auvi-Q |
| Genentech USA, INC. | $65.84 | 2024-2025 | Xolair |
| Amgen INC. | $48.69 | 2023-2024 | Tezspire |
| Octapharma USA, INC. | $34.12 | 2021 | |
| Galderma Laboratories, L.P. | $23.54 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $23.41 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $23.18 | 2019 | |
| Greer Laboratories, INC. | $16.81 | 2025 | Oralair |
| Alk-Abello, INC | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Chinen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.